What Gulf Biotech does

Gulf Biotech Company B.S.C. Closed is a privately held Bahraini pharmaceutical manufacturer founded in 2016, specializing in sterile injectable generic formulations. Operations are housed at a vertically integrated facility in the Bahrain International Investment Park, built on a 16,000 m2 plot with 20,000 m2 of built-up area. The facility produces injectable products in vials (2R to 100ml), prefilled syringes, ampoules, and cartridges, with a commercial portfolio of 17+ generic molecules spanning antibiotics (e.g., Clindamycin, Ciprofloxacin, Amikacin, Levofloxacin, Metronidazole), antifungals (Fluconazole), corticosteroids (Dexamethasone), antipsychotics (Haloperidol), antiemetics (Ondansetron), NSAIDs (Ketoprofen, Meloxicam), local anesthetics (Lidocaine), antiepileptics (Phenytoin), iron supplements (Iron Sucrose), antiparkinsonian agents (Biperiden), and related categories for diabetes, rheumatoid arthritis, and gastrointestinal conditions.

The manufacturing technology stack is anchored by German-engineered equipment from Bosch and other European vendors, including Bosch vial filling lines operating under isolator technology to achieve ISO 5/Grade A classification, multi-effect distillation or thermo-compressor Water for Injection (WFI) systems with 316L stainless steel distribution loops, lyophilization capabilities using freeze-drying microscopy and differential scanning calorimetry for cycle development, Class A/B background environments with differential pressure between 10–15 Pascal, and integrated digital systems with an in-house data center, 6-month surveillance retention, and swipe-card access control. Rated production capacity stands at approximately 22,000 vials per hour on the 2R line (18,000 for 6R, 12,000 for 10R) and roughly 48 million prefilled syringes annually at 10,000 units per hour, with secondary packaging covering blistering, assembly, printing, labeling, cartoning, and storage. Manufacturing systems are designed to FDA and EMEA aseptic standards.

The business model layers six revenue streams: own-label product sales of the generic injectable portfolio; contract manufacturing for sterile liquid, lyophilized, and prefilled syringe formats priced through fixed materials, component cost, cost-plus, or return-on-invested-capital models; R&D services covering pre-formulation, formulation, stability testing, and tech transfer; regulatory and technical documentation services including CTD-format dossiers, GMP documentation, DMFs, validation, training, and mock audits; product commercialization services spanning pre-launch, launch, and post-launch market entry into the Middle East; and secondary packaging services. Customer segments comprise healthcare institutions in MENA (hospitals and clinics needing affordable injectable supply), patients with serious conditions, and pharmaceutical companies seeking MENA manufacturing or market-entry partners. Distribution relies on a sales-led motion with authorized distributor networks across MENA (with Saudi Arabia as the largest single GCC market), and management has publicly signaled pursuit of expansion into the Far East, Canada, North America, and Latin America.

Name

Gulf Biotech

Legal name

Gulf Biotech Company B.S.C. Closed

Website

https://gulf-biotech.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Bahraini specialty pharmaceutical manufacturer founded in 2016, producing sterile injectable generic formulations for the MENA region through a vertically integrated Bosch-equipped facility, with contract manufacturing, R&D, regulatory, packaging, and commercialization services.

Ownership category

akta.pro rank

Product category

Sterile Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

• Sterile injectable manufacturing
• Generic pharmaceutical products
• Contract manufacturing services
• Lyophilized injectable products
• Pharmaceutical formulation development

Headquarters

HQ city

Hidd

HQ country

Bahrain

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Gulf Biotech offers contract manufacturing of sterile formulations including lyophilized vials, cartridges, ampoules, and prefilled syringes. They provide aseptic filling services for 1-20ml vials, 3-5ml cartridges, and various syringe sizes. Pricing models include fixed materials pricing, component cost pricing, cost plus pricing, and return on invested capital pricing models.
2. Product Sales - Injectable Formulations: Manufacturing and sale of generic pharmaceutical injectable products including antibiotics, gastro-intestinal products, dermatology, diabetes, rheumatoid arthritis treatments. Products include Clindamycin, Ciprofloxacin, Amikacin, Dexamethasone, Fluconazole, Haloperidol, Iron Sucrose, Ketoprofen, Levofloxacin, Lidocaine, Meloxicam, Metronidazole, Ondansetron, Acetaminophen, Phenytoin, Ranitidine, and Biperiden.
3. R&D and Product Development Services: R&D services for sterile formulations including pre-formulation and formulation development, sterile liquid formulation development, lyophilized formulation development, stability testing, and tech transfer services for sterile liquid injectable products.
4. Regulatory and Technical Documentation Services: Regulatory services including Product Registration and Dossiers in CTD format, GMP documentation, Drug Master File (DMF), Validation, Training, Documentation, Mock audits, and technical data generation for various country-specific regulatory requirements.
5. Product Commercialization Services: Product commercialization services in middle east market including pre-launch, launch, and post-launch product support, market strategies, licensing partner identification, pricing models, and product branding/positioning.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Gulf Biotech is a vertically integrated pharmaceutical manufacturer that develops, produces, and supplies sterile generic injectable formulations across vials, prefilled syringes, ampoules, and cartridges. Its product portfolio spans antibiotics, anti-inflammatories, antifungals, antipsychotics, anesthetics, antiepileptics, iron supplements, antiemetics, and metabolic treatments. In parallel, the company provides contract manufacturing, R&D and tech transfer, regulatory and technical documentation, product commercialization, and secondary packaging services to pharmaceutical companies and partners in the MENA region.

Product overview

Gulf Biotech is a specialty healthcare company focused on developing, manufacturing, and supplying generic pharmaceutical injectable formulations. The company operates a state-of-the-art manufacturing facility in Bahrain producing sterile formulations across multiple dosage forms: Vials (including Clindamycin, Ciprofloxacin, Amikacin, Dexamethasone, Fluconazole, Haloperidol, Iron Sucrose, Ketoprofen, Levofloxacin, Lidocaine, Meloxicam, Metronidazole, Ondansetron, Acetaminophen, Phenytoin, Ranitidine, and Biperiden), Prefilled Syringes, Ampoules, and Cartridges. The product portfolio spans therapeutic categories including antibiotics, antifungals, anti-inflammatories, antipsychotics, anesthetics, antiepileptics, and treatments for diabetes, rheumatoid arthritis, and other serious conditions. Beyond product manufacturing, Gulf Biotech offers a comprehensive suite of contract services including Contract Manufacturing, R&D, Technical Documentation, Product Commercialization, Packaging Services, and Quality Management—positioning the company as a vertically integrated pharmaceutical partner serving the MENA region.

Differentiator

Problem solved

Functional benefit

Products and services

• Clindamycin Injection

Quantifiable outcome

• Production capacity of 22,000 vials per hour for 2R vials, with capability to produce various vial sizes including up to 100ml
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Healthcare Professionals and ResearcherscoreStrategic or Co-development PartnerGulf Biotech collaborates with healthcare professionals and leading researchers from academia and industry to advance science and deliver patient solutions. Scientists work with researchers to understand disease expressions and embed patient population needs in science and innovation process. The company supports patient groups who provide valuable services to patient communities.
• Strategic Partners (Generic)coreStrategic or Co-development PartnerGulf Biotech establishes partnerships in product development, technology transfer, joint marketing, and new ventures for development and manufacturing of new therapeutic classes. The company offers partnership models including product manufacturing, new products development, product commercialization, regulatory approvals, products registrations, and contract manufacturing.
• Bosch (Germany)coreTechnology or IntegrationEquipment supplier for vial filling machines, water purification systems, insulin/solution manufacturing equipment, autoclaves, and inspection lines. Bosch technology enables the facility to achieve ISO 5/Grade A classification for sterile filling operations.
• Rieckerman (Germany)majorTechnology or IntegrationPlant designer for Gulf Biotech manufacturing facility. Responsible for overall facility design and construction planning in Bahrain International Investment Park.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical leader with significant sterile injectable manufacturing and emerging MENA presence through partnerships and approvals. Comparable on injectable generic product breadth and contract manufacturing scale.
• Dr. Reddy's Laboratories: Indian global generics and biosimilars manufacturer with sterile injectable capabilities and active emerging-market expansion. Comparable on vertically integrated generic injectable manufacturing and regulated-market strategy.
• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with significant sterile injectable capacity serving regulated and emerging markets. Comparable on large-scale sterile injectable manufacturing and competitive generic injectable positioning.

Direct peers

• Pharco Pharmaceuticals: Egyptian pharmaceutical group with manufacturing across multiple dosage forms including sterile injectables, supplying MENA and African markets. Comparable as a regional manufacturer of generic injectables with similar vertical integration.
• Julphar (Gulf Pharmaceutical Industries): UAE-based vertically integrated generic pharmaceutical manufacturer producing sterile injectables, oral solids, and other dosage forms across MENA markets. Most directly comparable peer given regional focus, multi-format manufacturing, and generic injectable portfolio.
• Hikma Pharmaceuticals: Jordan-headquartered global generic pharmaceutical company with a substantial sterile injectable business (Hikma Injectables) and strong MENA presence. Directly comparable on sterile injectable manufacturing scale and geographic overlap in GCC markets.
• Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical company developing and manufacturing branded generics and specialty products including injectables for MENA markets. Closely comparable as a regional Saudi-focused player with branded generic injectable ambitions.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi Arabian pharmaceutical manufacturer producing generics across multiple dosage forms including injectables for the GCC market. Comparable regional competitor targeting the same Saudi/MENA public procurement channels.

Regional players

• Atabay Pharmaceuticals: Turkish pharmaceutical manufacturer producing sterile injectables and other dosage forms, primarily serving Turkey and select regional markets. Comparable on sterile injectable manufacturing focus though operating in a different primary geography.

Others

• Bosch Packaging Technology (Pharma): Critical technology partner providing the Bosch vial filling line, water treatment, autoclaves, and inspection equipment that underpins Gulf Biotech's sterile injectable capability. Included as an ecosystem participant and key dependency rather than a competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/GBC115
• LinkedInlinkedin.com/company/gulf-biotech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gulf Biotech